Literature DB >> 22573283

Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?

Ahmet Turan Isik1, Ergun Bozoglu, Adnan Yay, Pinar Soysal, Umit Ateskan.   

Abstract

OBJECTIVE: Cholinesterase inhibitors (ChEIs) are widely used for the treatment of Alzheimer's disease (AD); however, their cholinergic side effects on the cardiovascular system are still unclear. In this study, we aimed to examine the side effects caused by donepezil, rivastigmine, and galantamine on cardiac rhythm and postural blood pressure changes in elderly patients with AD.
METHODS: Of 204 consecutive elderly patients who were newly diagnosed with AD, 162 were enrolled and underwent comprehensive geriatric assessments. The electrocardiographs (ECGs) and blood pressures were recorded at the baseline and 4 weeks after the dose of 10 mg/d of donepezil, 10 cm(2)/d of rivastigmine, and 24 mg/d of galantamine.
RESULTS: There were no changes relative to the baseline in any of the ECG parameters or arterial blood pressure with any of the administered ChEIs.
CONCLUSION: It was demonstrated that none of the 3 ChEIs were associated with increased negative chronotropic, arrhythmogenic, and hypotensive effects for the elderly patients with AD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22573283     DOI: 10.1177/1533317512442999

Source DB:  PubMed          Journal:  Am J Alzheimers Dis Other Demen        ISSN: 1533-3175            Impact factor:   2.035


  5 in total

Review 1.  An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine.

Authors:  Rita Khoury; Jayashree Rajamanickam; George T Grossberg
Journal:  Ther Adv Drug Saf       Date:  2018-01-08

2.  Management of Psychiatric Disorders in Patients with Cardiovascular Diseases.

Authors:  Prasad Rao Gundugurti; Ranjan Bhattacharyya; Amulya Koneru
Journal:  Indian J Psychiatry       Date:  2022-03-23       Impact factor: 2.983

Review 3.  Cardiovascular effects of drugs used to treat Alzheimer's disease.

Authors:  Laurence Guy Howes
Journal:  Drug Saf       Date:  2014-06       Impact factor: 5.606

4.  Triple Test Plus Rapid Cognitive Screening Test: A Combination of Clinical Signs and A Tool for Cognitive Assessment in Older Adults.

Authors:  Saadet Koc Okudur; Ozge Dokuzlar; Derya Kaya; Pinar Soysal; Ahmet Turan Isik
Journal:  Diagnostics (Basel)       Date:  2019-08-15

5.  Use of Drugs With Risk of Heart Rate-Related Problems is Common in Norwegian Dementia Patients Treated With Acetylcholinesterase Inhibitors: A Prevalence Study Based on the Norwegian Prescription Database.

Authors:  Anne Sverdrup Efjestad; Hege Ihle-Hansen; Vidar Hjellvik; Knut Engedal; Hege Salvesen Blix
Journal:  Front Pharmacol       Date:  2022-02-22       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.